<p>Belite Bio, Inc. 赞助的 ADR (NASDAQ:BLTE - 获取免费报告) 在周一的午盘交易中上涨了 5.5%。该公司交易价格最高达到 $158.94，最后交易价格为 $163.4850。在交易中，共成交 75,031 股，较平均交易量 75,671 股下降了 1%。该股票此前收盘价为 $154.93。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>三个鲜为人知的医疗保健公司，未来有重大上涨潜力</li>
</ul>
<p>BLTE 已成为多份分析师报告的主题。BTIG Research 在 12 月 3 日的报告中将 Belite Bio 的目标股价设定为 $187.00。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Belite Bio 的 &#34;卖出 (d-)&#34; 评级。Benchmark 在 12 月 3 日的报告中重申了对 Belite Bio 的 &#34;买入&#34; 评级。Maxim Group 在 12 月 2 日的研究报告中将 Belite Bio 的目标价设定为 $200.00。最后，Wall Street Zen 在周六的研究报告中将 Belite Bio 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。四位股票研究分析师给予该股票 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，平均目标价为 $175.33。</p>
<p><strong>查看我们最新的 BLTE 股票报告</strong></p>
<h2>Belite Bio 价格表现</h2>
<p>该公司的 50 日移动平均线为 $126.91，200 日移动平均线为 $87.90。该公司的市值为 63.4 亿美元，市盈率为 -88.23，贝塔值为 -1.45。</p>
<p>Belite Bio (NASDAQ:BLTE - 获取免费报告) 最近在 12 月 1 日宣布了其季度财报。该公司报告本季度每股收益为 $0.95。整体来看，股票分析师预测 Belite Bio, Inc. 赞助的 ADR 本年度将发布 -1.17 的每股收益。</p>
<h2>机构投资者对 Belite Bio 的看法</h2>
<p>几家大型投资者最近对 BLTE 的持仓进行了调整。美国银行在第三季度将其在 Belite Bio 的持仓提高了 28.1%。美国银行目前拥有该公司 1,171 股股票，价值 $87,000，此前在上个季度增持了 257 股。GAMMA Investing LLC 在第三季度将其在 Belite Bio 的持仓增加了 11.1%。GAMMA Investing LLC 目前拥有该公司 1,758 股股票，价值 $130,000，此前在上个季度增持了 176 股。EverSource Wealth Advisors LLC 在第二季度获得了 Belite Bio 的新头寸，价值约 $147,000。法国巴黎银行金融市场在第二季度获得了 Belite Bio 的新股份，价值约 $190,000。最后，Ameriprise Financial Inc. 在第三季度购买了 Belite Bio 的新股份，价值 $224,000。机构投资者持有该公司 0.53% 的股票。</p>
<h2>Belite Bio 公司简介</h2>
<p>(获取免费报告)</p>
<p>Belite Bio, Inc NASDAQ: BLTE 是一家临床阶段的生物技术公司，专注于发现和开发用于代谢和炎症疾病的小分子治疗药物。该公司利用专有的药物发现平台，旨在通过针对纤维化、炎症和代谢调节相关的通路，解决非酒精性脂肪性肝炎 (NASH) 和肥胖等疾病。</p>
<p>Belite Bio 的产品管线包括多个处于临床前和早期临床开发阶段的候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Belite Bio</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>$1M 在退休中能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Belite Bio 吗？</h2>
<p>在你考虑投资 Belite Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Belite Bio 并不在名单上。</p>
<p>虽然 Belite Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BLTE

<p>Belite Bio（NASDAQ:BLTE）股票在午盘交易中上涨了 5.5%，达到 163.49 美元的高点。分析师们的意见不一，BTIG 设定的目标价为 187 美元，而 Weiss Ratings 维持 “卖出” 评级。该股票的共识评级为 “适度买入”，平均目标价为 175.33 美元。机构投资者增加了持股比例，目前持股为 0.53%。Belite Bio 专注于开发代谢和炎症疾病的治疗药物，市值为 63.4 亿美元，市盈率为-88.23</p>

<p>Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) traded up 5.5% during mid-day trading on Monday . The company traded as high as $158.94 and last traded at $163.4850. 75,031 shares traded hands during trading, a decline of 1% from the average session volume of 75,671 shares. The stock had previously closed at $154.93.</p>
<div class="lb-trans"><p>Belite Bio, Inc. 赞助的 ADR (NASDAQ:BLTE - 获取免费报告) 在周一的午盘交易中上涨了 5.5%。该公司交易价格最高达到 $158.94，最后交易价格为 $163.4850。在交易中，共成交 75,031 股，较平均交易量 75,671 股下降了 1%。该股票此前收盘价为 $154.93。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>3 Lesser-Known Healthcare Names With Major Upside in Store</li>
</ul>
<div class="lb-trans"><ul>
<li>三个鲜为人知的医疗保健公司，未来有重大上涨潜力</li>
</ul>
</div><p>BLTE has been the subject of several analyst reports. BTIG Research set a $187.00 price target on shares of Belite Bio in a report on Wednesday, December 3rd. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Belite Bio in a research report on Wednesday, October 8th. Benchmark reaffirmed a &#34;buy&#34; rating on shares of Belite Bio in a report on Wednesday, December 3rd. Maxim Group set a $200.00 price objective on Belite Bio in a research note on Tuesday, December 2nd. Finally, Wall Street Zen upgraded Belite Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $175.33.</p>
<div class="lb-trans"><p>BLTE 已成为多份分析师报告的主题。BTIG Research 在 12 月 3 日的报告中将 Belite Bio 的目标股价设定为 $187.00。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Belite Bio 的 &#34;卖出 (d-)&#34; 评级。Benchmark 在 12 月 3 日的报告中重申了对 Belite Bio 的 &#34;买入&#34; 评级。Maxim Group 在 12 月 2 日的研究报告中将 Belite Bio 的目标价设定为 $200.00。最后，Wall Street Zen 在周六的研究报告中将 Belite Bio 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。四位股票研究分析师给予该股票 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，平均目标价为 $175.33。</p>
</div><p><strong>View Our Latest Stock Report on BLTE</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 BLTE 股票报告</strong></p>
</div><h2>Belite Bio Price Performance</h2>
<div class="lb-trans"><h2>Belite Bio 价格表现</h2>
</div><p>The business has a 50 day moving average of $126.91 and a 200 day moving average of $87.90. The firm has a market capitalization of $6.34 billion, a price-to-earnings ratio of -88.23 and a beta of -1.45.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 $126.91，200 日移动平均线为 $87.90。该公司的市值为 63.4 亿美元，市盈率为 -88.23，贝塔值为 -1.45。</p>
</div><p>Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Monday, December 1st. The company reported $0.95 EPS for the quarter. As a group, equities analysts predict that Belite Bio, Inc. Sponsored ADR will post -1.17 EPS for the current year.</p>
<div class="lb-trans"><p>Belite Bio (NASDAQ:BLTE - 获取免费报告) 最近在 12 月 1 日宣布了其季度财报。该公司报告本季度每股收益为 $0.95。整体来看，股票分析师预测 Belite Bio, Inc. 赞助的 ADR 本年度将发布 -1.17 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Belite Bio</h2>
<div class="lb-trans"><h2>机构投资者对 Belite Bio 的看法</h2>
</div><p>Several large investors have recently made changes to their positions in BLTE. Bank of America Corp DE lifted its position in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock valued at $87,000 after acquiring an additional 257 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company's stock worth $130,000 after buying an additional 176 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in Belite Bio during the 2nd quarter worth approximately $147,000. BNP Paribas Financial Markets acquired a new stake in shares of Belite Bio in the second quarter valued at approximately $190,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of Belite Bio in the third quarter worth $224,000. Institutional investors own 0.53% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对 BLTE 的持仓进行了调整。美国银行在第三季度将其在 Belite Bio 的持仓提高了 28.1%。美国银行目前拥有该公司 1,171 股股票，价值 $87,000，此前在上个季度增持了 257 股。GAMMA Investing LLC 在第三季度将其在 Belite Bio 的持仓增加了 11.1%。GAMMA Investing LLC 目前拥有该公司 1,758 股股票，价值 $130,000，此前在上个季度增持了 176 股。EverSource Wealth Advisors LLC 在第二季度获得了 Belite Bio 的新头寸，价值约 $147,000。法国巴黎银行金融市场在第二季度获得了 Belite Bio 的新股份，价值约 $190,000。最后，Ameriprise Financial Inc. 在第三季度购买了 Belite Bio 的新股份，价值 $224,000。机构投资者持有该公司 0.53% 的股票。</p>
</div><h2>Belite Bio Company Profile</h2>
<div class="lb-trans"><h2>Belite Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.</p>
<div class="lb-trans"><p>Belite Bio, Inc NASDAQ: BLTE 是一家临床阶段的生物技术公司，专注于发现和开发用于代谢和炎症疾病的小分子治疗药物。该公司利用专有的药物发现平台，旨在通过针对纤维化、炎症和代谢调节相关的通路，解决非酒精性脂肪性肝炎 (NASH) 和肥胖等疾病。</p>
</div><p>Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.</p>
<div class="lb-trans"><p>Belite Bio 的产品管线包括多个处于临床前和早期临床开发阶段的候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Belite Bio</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Belite Bio</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>$1M 在退休中能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Belite Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Belite Bio 吗？</h2>
</div><p>Before you consider Belite Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Belite Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Belite Bio 并不在名单上。</p>
</div><p>While Belite Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Belite Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Belite Bio（纳斯达克股票代码：BLTE）股价上涨 5.5% - 你是否应该购买？